[1] Gharib H, Papini E, Garber JR, et al.  American association of clinical endocrinologists, american college of endocrinology, and associazione medici endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules-2016 up date[J]. Endocr Pract, 2016, 22(5): 622-639.   doi: 10.4158/EP161208.GL
[2] Kuzu F, Arpazi D, Unal M, et al.  Midkine: a novel biomarker to predict malignancy in patients with nodular thyroid disease[J]. Int J Endocrinol, 2016, 2016: 6035024-.   doi: 10.1155/2016/6035024
[3] Czepczyński R, Stangierski A, Oleksa R, et al.  Incidental 18F-FDG uptake in the thyroid in patients diagnosed with PET/CT for other malignancies[J]. Nucl Med Rev Cent East Eur, 2011, 14(2): 68-72.   doi: 10.5603/NMR.2011.00018
[4] Barrio M, Czernin J, Yeh MW, et al.  The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients[J]. Nucl Med Commun, 2016, 37(12): 1290-1296.   doi: 10.1097/MNM.0000000000000592
[5] Muramatsu T, Kadomatsu K.  Midkine: an emerging target of drug development for treatment of multiple diseases[J]. Br J Pharmacol, 2014, 171(4): 811-813.   doi: 10.1111/bph.12571
[6] 李春红, 曹鸿艳, 蔡莉.  Galectin-3的抗凋亡机制及其在肺癌中的研究[J]. 国际免疫学杂志, 2008, 31(3): 229-232.   doi: 10.3760/cma.j.issn.1673-4394.2008.03.019
Li CH, Cao HY, Cai L.  Research on anti-apoptosis mechanism of Galectin-3 and the expression in lung cancer[J]. Int J Immunol, 2008, 31(3): 229-232.   doi: 10.3760/cma.j.issn.1673-4394.2008.03.019
[7]

Sun B, Hu CL, Yang ZB, et al. Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells[J/OL]. Oncotarget, 2017, 8(20): 32523−32535[2019-06-01]. https://pubmed.ncbi.nlm.nih.gov/28430645/. DOI: 10.18632/oncotarget.15808.
[8] 薛刚, 刘军超, 黄静, 等.  血清与组织glactin-3 联合检测在甲状腺癌早期诊断中的价值[J]. 南方医科大学学报, 2013, 33(7): 1027-1030.   doi: 10.3969/j.issn.1673-4254.2013.07.18
Xue G, Liu JC, Huang J, et al.  Detection of glactin-3 in both serum and tissue for early diagnosis of thyroid carcinoma[J]. J South Med Univ, 2013, 33(7): 1027-1030.   doi: 10.3969/j.issn.1673-4254.2013.07.18
[9] Meng ZW, Tan J, Zhang GZ, et al.  Evaluation of serum midkine as a biomarker in differentiated thyroid cancer[J]. Life Sci, 2015, 130: 18-24.   doi: 10.1016/j.lfs.2015.02.028
[10] 冯光勇, 黄伟.  血清肝素结合生长因子对分化型甲状腺肿瘤诊断及临床预后的评估价值[J]. 临床血液学杂志, 2017, 30(8): 600-604.   doi: 10.13201/j.issn.1004-2806-b.2017.08.007
Feng GY, Huang W.  Diagnosis and prognosis prediction value of serum midkine in differentiated thyroid cancer[J]. J Clin Hematol, 2017, 30(8): 600-604.   doi: 10.13201/j.issn.1004-2806-b.2017.08.007
[11]

Jing X, Cui XR, Liang HP, et al. Diagnostic accuracy of ELISA for detecting serum Midkine in cancer patients[J/OL]. PLoS One, 2017, 12(7): e0180511[2019-06-01]. https://pubmed.ncbi.nlm.nih.gov/28686647/. DOI:10.1371/journal.pone.0180511
[12] 李田军, 林岩松, 梁军, 等.  131I治疗前刺激性Tg对乳头状甲状腺癌远处转移的预测价值[J]. 中华核医学与分子影像杂志, 2012, 32(3): 189-191.   doi: 10.3760/cma.j.issn.2095-2848.2012.03.007
Li TJ, Lin YS, Liang J, et al.  The value of pre-ablation stimulated thyroglobulin in predicting distant metastasis of papillary thyroid cancer[J]. Chin J Nucl Med Mol Imaging, 2012, 32(3): 189-191.   doi: 10.3760/cma.j.issn.2095-2848.2012.03.007
[13] Jee YH, Celi FS, Sampson M, et al.  Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules[J]. Clin Endocrinol (Oxf), 2015, : 83-.   doi: 10.1111/cen.12676
[14] Sorrelle N, Dominguez ATA, Brekken RA, et al.  From top to bottom: midkine and pleiotrophin as emerging players in immune regulation[J]. J Leukoc Biol, 2017, 102(2): 277-286.   doi: 10.1189/jlb.3MR1116-475R
[15] Dumic J, Dabelic S, Flögel M.  Galectin-3: an open-ended story[J]. Biochim Biophys Acta, 2006, 1760(4): 616-635.   doi: 10.1016/j.bbagen.2005.12.020
[16] 佟杰, 王岩, 笪冀平.  CK19 HBME-1 Galectin-3等表达在甲状腺乳头状微小癌与良性病变鉴别诊断中的意义[J]. 中华肿瘤杂志, 2011, 33(8): 599-604.   doi: 10.3760/cma.j.issn.0253-3766.2011.08.010
Tong J, Wang Y, Da JP.  Usefulness of CK19, HBME-1 and Galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions[J]. Chin J Oncol, 2011, 33(8): 599-604.   doi: 10.3760/cma.j.issn.0253-3766.2011.08.010
[17] Saussez S, Glinoer D, Chantrain G, et al.  Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease[J]. Thyroid, 2008, 18(7): 705-712.   doi: 10.1089/thy.2007.0361
[18]

Dobrescu R, Schipor S, Manda D, et al. Does serum Galectin-3 add value in thyroid cancer diagnosis?[J/OL]. Endocrine Abstracts, 2016, 41: GP232[2019-06-01]. https://www.endocrine-abstracts.org/ea/0041/ea0041GP232.htm. DOI: 10.1530/endoabs.41.GP232.
[19] 任丽丽, 耿建.  老年结肠癌病人循环与肿瘤组织中Galectin-3水平及临床意义[J]. 实用老年医学, 2017, 31(2): 153-156.   doi: 10.3969/j.issn.1003-9198.2017.02.015
Ren LL, Geng J.  Clinical and prognostic effects of Galectin-3 in elderly patients with colorectal cancer[J]. Pract Geriatr, 2017, 31(2): 153-156.   doi: 10.3969/j.issn.1003-9198.2017.02.015
[20] 尚培中, 柳勇, 李永庆, 等.  COX-2和Gal-3表达与甲状腺乳头状癌浸润转移的关系[J]. 河北北方学院学报: 自然科学版, 2016, 32(8): 1-4.   doi: 10.3969/j.issn.1673-1492.2016.08.001
Shang PZ, Liu Y, Li YQ, et al.  Expressions of COX-2 and Gal-3 and invasion and metastasis in papillary thyroid carcinoma[J]. J Hebei North Univ (Natur Sci), 2016, 32(8): 1-4.   doi: 10.3969/j.issn.1673-1492.2016.08.001
[21] 刘燕青.  甲状腺癌患者血清中galectin-3、midkine含量测定对肿瘤病情评估的价值[J]. 海南医学院学报, 2017, 23(3): 418-421.   doi: 10.13210/j.cnki.jhmu.20161124.001
Liu YQ.  Value of serum galectin-3 and midkine level for assesing tumor severity in patients with thyriod cancer[J]. J Hainan Med Univ, 2017, 23(3): 418-421.   doi: 10.13210/j.cnki.jhmu.20161124.001
[22]

Zheng JJ, Lu WH, Wang C, et al. Galectin-3 induced by hypoxia promotes cell migration in thyroid cancer cells[J/OL]. Oncotarget, 2017, 8(60): 101475−101488[2019-06-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731889/. DOI:10.18632/oncotarget.21135.